CALL/EVOTEC/35/0.1/20.12.24 Share Price

Warrant

DE000GP5E395

Market Closed - BOERSE MUENCHEN 09:55:59 07/06/2024 pm IST
0.024 EUR +4.35% Intraday chart for CALL/EVOTEC/35/0.1/20.12.24
Current month+50.00%
1 month-14.29%
Date Price Change
07/24/07 0.024 +4.35%
06/24/06 0.023 0.00%
05/24/05 0.023 0.00%
04/24/04 0.023 +53.33%
03/24/03 0.015 -6.25%

Real-time BOERSE MUENCHEN

Last update June 07, 2024 at 09:55 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP5E39
ISINDE000GP5E395
Date issued 05/06/2023
Strike 35
Maturity 20/12/2024 (194 Days)
Parity 10 : 1
Emission price 0.11
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.314
Lowest since issue 0.014
Delta0.11x
Omega 3.420
Premium299.55x
Gearing31.54x
Moneyness 0.2523
Difference Strike 26.17
Difference Strike %+74.77%
Spread 0.01
Spread %30.30%
Theoretical value 0.0280
Implied Volatility 112.43 %
Total Loss Probability 98.02 %
Intrinsic value 0.000000
Present value 0.0280
Break even 35.28 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.83 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.45%
Consensus